Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New Technology Halves Time Currently Taken to Identify If Positive COVID-19 Sample Contains Variant of Concern

By LabMedica International staff writers
Posted on 01 Apr 2021
A groundbreaking new technology to rapidly detect new COVID mutations indicating whether positive test samples contain known variants is being trialed by the UK government.

The technology - known as ‘genotype assay testing’ - is being trialed by the UK government in NHS Test and Trace (England) laboratories is set to halve the time it currently takes to identify if a positive COVID-19 sample contains a variant of concern, and could be used in addition to standard testing for COVID-19 to identify cases quickly.

The new technology will mean that cases of variants of concern are detected faster than before - potentially halving the time it takes to detect a case, which is currently around four to five days for genomic sequencing. More...
By notifying those affected more quickly, this could allow contacts of positive cases to be traced sooner, breaking the chains of transmission, stop the spread of variants and saving lives.

Genotype assays would complement existing surveillance work that uses genomic sequencing to look for variants in COVID-positive samples. Genomic sequencing surveillance will continue to detect new variants and mutations. Where new variants or mutations are identified, the technology could be adapted to test for them as well, meaning the technology can be easily deployed to track the variants of most concern.

“Innovation is at the heart of our fight against COVID-19 and has a key part to play in controlling the spread of the virus. We must not stand still if we are to beat COVID-19 and safely ease restrictions in the coming months,” said UK Health and Social Care Secretary Matt Hancock. “That is why our goal is to eventually test every COVID positive sample for mutations, that indicate known variants, using this ground breaking new technology. This type of testing will help us rapidly identify variant cases and trace contacts quicker than ever before, helping stop outbreaks in their tracks and ensuring we can continue to follow the roadmap we have set out to get back to normal life.”

Related Links:
NHS Test and Trace


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Portable Electronic Pipette
Mini 96
New
Pipette
Accumax Smart Series
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: AiPlex VAS for the MosaiQ platform is designed to help reduce time-to-diagnosis for patients with autoimmune vasculitis (Photo courtesy of AliveDx)

Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis

Autoimmune vasculitis and related conditions are difficult to diagnose quickly and accurately, often requiring multiple tests to confirm the presence of specific autoantibodies. Traditional methods can... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.